MENU

Fox Chase Cancer Center News

February 14, 2020

Cukierman Named Fellow of the American Gastroenterological Association

PHILADELPHIA (February 14, 2020) – Dr. Cukierman's induction as a fellow is notable because historically AGA has been a medical association. Cukierman is not a medical doctor, but she joined AGA in order to better understand the medical side of gastroenterology.

February 13, 2020

Fox Chase Featured as Cancer Center of Excellence in One of Journal of Oncology Practice’s Most-Read 2019 Articles

PHILADELPHIA (February 13, 2020) – A research article featuring featured Fox Chase Cancer Center  was awarded the 2019 Journal of Oncology Practice (JOP) Editor’s Pick Award for being one of the top five most-read articles published in JOP in 2019.

February 10, 2020

Gene May Play Bigger Role in Kidney Cancer Than Previously Thought

PHILADELPHIA (February 10, 2020)—Its involvement in causing over 50 percent of all cancers makes p53 one of the most well-known cancer genes. But there are some malignancies, like kidney cancer, that rarely have p53 mutations.

February 5, 2020

Expanded Database Should Allow Easier Access to Information on Protein Interactions

PHILADELPHIA (February 5, 2020) –Roland L. Dunbrack Jr., PhD, director of the Molecular Modeling Facility at Fox Chase Cancer Center, and his team have updated their Protein Common Interface Database (ProtCID) to include data on the individual domain level, which greatly increases the number of large protein-protein clusters available in the database.

 

The ANCC accreditation will last until May 2023, at which point the program will need to apply for re-accreditation.
February 4, 2020

Fox Chase Cancer Center Earns Accreditation From American Nurses Credentialing Center

PHILADELPHIA (February 4, 2020) – Fox Chase Cancer Center has announced that its Nurse Residency Program achieved ANCC Practice Transition Accreditation with Distinction, the highest recognition awarded.

 “There were four institutions who participated in this trial, enrolling 20 patients in less than six months, showing that these types of studies can be accomplished in a relatively short period of time.”
February 3, 2020

IGF-1R a Marker for, but Not Driving Wild-Type GIST

PHILADELPHIA (February 3, 2020) – Although insulin-like growth factor receptor-1 (IGF-R1) is a biomarker for wild-type gastrointestinal stromal tumors (GIST), these mutations do not appear to be driving the disease, according to the results of a study from researchers at Fox Chase Cancer Center.

Scientist and biostatistician Brian L. Egleston, MPP, PhD
February 3, 2020

Fox Chase Biostatistician Brings Trial Design Expertise to MyCancerGene Study

PHILADELPHIA (February 3, 2020) – Scientist and biostatistician Brian L. Egleston, MPP, PhD, of Fox Chase Cancer Center, will be teaming with scientists at the University of Pennsylvania on a series of studies that will attempt to develop methods for better communicating genetic test results to patients.

The OCRA Liz Tilberis Early Career Award provides James Duncan, PhD, with a three-year grant of $150,000 per year for research on ovarian cancer
January 28, 2020

James Duncan Receives Grant for Research on Combo Therapy to Treat High-Grade Serous Ovarian Carcinoma

PHILADELPHIA (January 28, 2020) – The OCRA Liz Tilberis Early Career Award provides James Duncan, PhD, and seven other 2020 award winners with a three-year grant of $150,000 per year to support their research on ovarian cancer.

Pages

Connect with Fox Chase